The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York
Open accessAbstract
Importance: New York State (NYS) is an epicenter of the United States' COVID-19 epidemic. Reliable estimates of cumulative incidence of SARS-CoV-2 infection in the population are critical to tracking the extent of transmission and informing policies, but US data are lacking, in part because societal closure complicates study conduct. Objective: To estimate the cumulative incidence of SARS-CoV-2 infection and percent of infections diagnosed in New York State, overall and by region, age, sex, and race and ethnicity. Design: Statewide cross-sectional seroprevalence study, conducted April 19-28, 2020. Setting: Grocery stores (n=99) located in 26 counties throughout NYS, which were essential businesses that remained open during a period of societal closure and attract a heterogenous clientele. Participants: Convenience sample of patrons >=18 years and residing in New York State, recruited consecutively upon entering stores and via an in-store flyer. Exposures: Region (New York City, Westchester/Rockland, Long Island, Rest of New York State), age, sex, race and ethnicity. Main Outcomes: Primary outcome: cumulative incidence of SARS-CoV-2 infection, based on dry-blood spot (DBS) SARS-CoV-2 antibody reactivity; secondary outcome: percent of infections diagnosed. Results: Among 15,101 adults with suitable DBS specimens, 1,887 (12.5%) were reactive using a validated SARS-CoV-2 IgG microsphere immunoassay (sensitivity 87.9%, specificity 99.75%). Following post-stratification weighting on region, sex, age, and race and ethnicity and adjustment for assay characteristics, estimated cumulative incidence through March 29 was 14.0% (95% CI: 13.3-14.7%), corresponding to 2,139,300 (95% CI: 2,035,800-2,242,800) infection-experienced adults. Cumulative incidence was higher among Hispanic/Latino (29.2%, 95% CI: 27.2-31.2%), non-Hispanic black/African American (20.2% 95% CI, 18.1-22.3%), and non-Hispanic Asian (12.4%, 95% CI: 9.4-15.4%) adults than non-Hispanic white adults (8.1%, 95% CI: 7.4-8.7%, p<.0001). Cumulative incidence was highest in New York City (NYC) 22.7% (95% CI: 21.5%-24.0). Dividing diagnoses reported to NYS by estimated infection-experienced adults, an estimated 8.9% (95% CI: 8.4-9.3%) of infections were diagnosed, with those [≥]55 years most likely to be diagnosed (11.3%, 95% CI: 10.4-12.2%). Conclusions and Relevance: Over 2 million adults were infected through late March 2020, with substantial variations by subpopulations. As this remains below herd immunity thresholds, monitoring, testing, and contact tracing remain essential public health strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Li, R., Pei, S., Chen, B., Song, Y., Zhang, T., Yang, W., & Shaman, J. (2020) · Science · doi:10.1126/science.abb3221 · Cited by 3,633
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607
Clinical Characteristics of Covid-19 in New York City
Goyal, P., Choi, J. J., Pinheiro, L. C., Schenck, E. J., Chen, R., Jabri, A., Satlin, M. J., Campion, T. R., Nahid, M., Ringel, J. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2010419 · Cited by 2,234
Rothman, K. J., Greenland, S., & Lash, T. L. (1998) · Cited by 2,096
Hospitalization and mortality among Black patients and White patients with Covid-19.
Price-Haywood, E. G., Burton, J., Fort, D., & Seoane, L. (2020) · New England Journal of Medicine · doi:10.1056/nejmsa2011686 · Cited by 1,660
Interpreting Diagnostic Tests for SARS-CoV-2
Sethuraman, N., Jeremiah, S. S., & Ryo, A. (2020) · JAMA · doi:10.1001/jama.2020.8259 · Cited by 1,494
Rao, J. N. K., & Scott, A. J. (1984) · The Annals of Statistics · doi:10.1214/aos/1176346391 · Cited by 1,280
Spread of SARS-CoV-2 in the Icelandic population
Gudbjartsson, D. F., Helgason, A., Jonsson, H., Magnusson, O. T., Melsted, P., Norddahl, G. L., Saemundsdottir, J., Sigurdsson, A., Sulem, P., Agustsdottir, A. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2006100 · Cited by 1,248
Assessing differential impacts of COVID-19 on black communities
Millett, G. A., Jones, A. T., Benkeser, D., Baral, S., Mercer, L., Beyrer, C., Honermann, B., Lankiewicz, E., Mena, L., Crowley, J. S., et al. (2020) · Annals of Epidemiology · doi:10.1016/j.annepidem.2020.05.003 · Cited by 1,217
Rosenberg, E. S., Dufort, E. M., Udo, T., Wilberschied, L. A., Kumar, J., Tesoriero, J., Weinberg, P., Kirkwood, J., Muse, A., DeHovitz, J., et al. (2020) · JAMA · doi:10.1001/jama.2020.8630 · Cited by 1,156
Self-citationKimball, A., Hatfield, K. M., Arons, M., James, A., Taylor, J., Spicer, K., Bardossy, A. C., Oakley, L. P., Tanwar, S., Chisty, Z., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6913e1 · Cited by 1,050
Korn, E. L., & Graubard, B. I. (1999) · Wiley eBooks · doi:10.1002/9781118032619 · Cited by 1,044
Coronavirus disease 2019 (COVID-19) in Italy
Livingston, E., & Bucher, K. (2020) · JAMA · doi:10.1001/jama.2020.4344 · Cited by 1,010
(2001) · Technometrics · doi:10.1198/tech.2001.s612 · Cited by 989
Racial health disparities and covid-19 - caution and context
Chowkwanyun, M., & Reed, A. L. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2012910 · Cited by 706
COVID-19 antibody seroprevalence in santa clara county, california
Bendavid, E., Mulaney, B., Sood, N., Shah, S., Bromley-Dulfano, R., Lai, C., Weissberg, Z., Saavedra-Walker, R., Tedrow, J., Bogan, A., et al. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyab010 · Cited by 669
Azar, K. M. J., Shen, Z., Romanelli, R. J., Lockhart, S. H., Smits, K., Robinson, S., Brown, S., & Pressman, A. R. (2020) · Health Affairs · doi:10.1377/hlthaff.2020.00598 · Cited by 559
Antibody Detection and Dynamic Characteristics in Patients With Coronavirus Disease 2019
Xiang, F., Wang, X., He, X., Peng, Z., Yang, B., Zhang, J., Zhou, Q., Ye, H., Ma, Y., Li, H., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa461 · Cited by 535
Herd immunity – estimating the level required to halt the COVID-19 epidemics in affected countries
Kwok, K. O., Lai, F., Wei, W. I., Wong, S. Y. S., & Tang, J. W. T. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.027 · Cited by 499
Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013‐2016
Hofmeister, M. G., Rosenthal, E. M., Barker, L. K., Rosenberg, E. S., Barranco, M. A., Hall, E. W., Edlin, B. R., Mermin, J., Ward, J. W., & Ryerson, A. B. (2019) · Hepatology · doi:10.1002/hep.30297 · Cited by 486
Self-citationHigh population densities catalyse the spread of COVID-19
Rocklöv, J., & Sjödin, H. (2020) · Journal of Travel Medicine · doi:10.1093/jtm/taaa038 · Cited by 415
Sood, N., Simon, P., Ebner, P., Eichner, D., Reynolds, J., Bendavid, E., & Bhattacharya, J. (2020) · JAMA · doi:10.1001/jama.2020.8279 · Cited by 406
Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China
Xu, X., Sun, J., Nie, S., Li, H., Kong, Y., Liang, M., Hou, J., Huang, X., Li, D., Ma, T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0949-6 · Cited by 405
COVID-19 in a Long-Term Care Facility — King County, Washington, February 27–March 9, 2020
McMichael, T. M., Clark, S., Pogosjans, S., Kay, M., Lewis, J., Baer, A., Kawakami, V., Lukoff, M. D., Ferro, J., Brostrom-Smith, C., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6912e1 · Cited by 382
Nishiura, H., Kobayashi, T., Yang, Y., Hayashi, K., Miyama, T., Kinoshita, R., Linton, N., Jung, S.-M., Yuan, B., Suzuki, A., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020419 · Cited by 286
Holt, D., & Smith, T. M. F. (1979) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344652 · Cited by 257
COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions
Kirkcaldy, R. D., King, B. A., & Brooks, J. T. (2020) · JAMA · doi:10.1001/jama.2020.7869 · Cited by 229
Rosenberg, E. S., Dufort, E. M., Blog, D. S., Hall, E. W., Hoefer, D., Backenson, B. P., Muse, A. T., Kirkwood, J. N., St. George, K., Holtgrave, D. R., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa549 · Cited by 166
Self-citationDynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients
Lee, Y.-L., Liao, C.-H., Liu, P., Cheng, C., Chung, M., Liu, C.-E., Chang, S., & Hsueh, P. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.04.019 · Cited by 137
Using Early Data to Estimate the Actual Infection Fatality Ratio from COVID-19 in France
Roques, L., Klein, E. K., Papaix, J. J., Sar, A., & Soubeyrand, S. (2020) · Biology · doi:10.3390/biology9050097 · Cited by 119
Reopening Society and the Need for Real-Time Assessment of COVID-19 at the Community Level
Angulo, F. J., Finelli, L., & Swerdlow, D. L. (2020) · JAMA · doi:10.1001/jama.2020.7872 · Cited by 44
Cited by
Age-specific mortality and immunity patterns of SARS-CoV-2
O’Driscoll, M., Ribeiro Dos Santos, G., Wang, L., Cummings, D. A. T., Azman, A. S., Paireau, J., Fontanet, A., Cauchemez, S., & Salje, H. (2021) · Nature · doi:10.1038/s41586-020-2918-0 · Cited by 1,210
Mackey, K., Ayers, C. K., Kondo, K. K., Saha, S., Advani, S. M., Young, S., Spencer, H., Rusek, M., Anderson, J., Veazie, S., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m20-6306 · Cited by 1,076
Levin, A. T., Hanage, W. P., Owusu-Boaitey, N., Cochran, K. B., Walsh, S. P., & Meyerowitz-Katz, G. (2020) · European Journal of Epidemiology · doi:10.1007/s10654-020-00698-1 · Cited by 844
COVID-19 antibody seroprevalence in santa clara county, california
Bendavid, E., Mulaney, B., Sood, N., Shah, S., Bromley-Dulfano, R., Lai, C., Weissberg, Z., Saavedra-Walker, R., Tedrow, J., Bogan, A., et al. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyab010 · Cited by 669
Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23–May 12, 2020
Havers, F. P., Reed, C., Lim, T., Montgomery, J. M., Klena, J. D., Hall, A. J., Fry, A. M., Cannon, D. L., Chiang, C.-F., Gibbons, A., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.4130 · Cited by 647
Metadata
- Authors
- Rosenberg, E. S., Tesoriero, J. M., Rosenthal, E. M., Chung, R., Barranco, M. A., Styer, L. M., Parker, M. M., John Leung, S.-Y., Morne, J. E., Greene, D., Holtgrave, D. R., Hoefer, D., Kumar, J., Udo, T., Hutton, B., & Zucker, H. A.
- Venue
- Annals of Epidemiology
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 48
- Pages
- 23-29.e4
- ISSN
- 1047-2797 (ISSN-L)
- OpenAlex
- W3035551180
- Cited by
- 262
- References
- 31
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.